Wegovy pill launch draws new patients into GLP-1 weight-loss treatment

Novo Nordisk's oral Wegovy pill has generated rapid prescription growth since its January launch, with company disclosures citing more than 600,000 prescriptions and many new users who had avoided GLP-1 injections; rivals such as Eli Lilly have recently gained approval for competing pills.

Novo Nordisk introduced an oral version of its Wegovy GLP-1 weight-loss medicine in January, and the product saw rapid early demand. Many people who had not used GLP-1 injections — because of cost or a fear of needles — sought the pill instead. Observers have noted that it is too soon to judge long-term outcomes or market share shifts. Key points: - Novo disclosed in February that more than 600,000 prescriptions had been written for the Wegovy pill since its launch. - Early uptake appears to have come largely from patients new to branded GLP-1 therapies rather than from users switching from injections. - Reported cash prices range roughly from $149 to $299 per month, with an initial entry price cited at $149. - The article mentions competition from Eli Lilly, which recently won U.S. approval for its own GLP-1 obesity pill, and that Novo's stock did not show a marked rise after the pill's debut. Summary: The pill's launch has broadened the pool of patients seeking GLP-1 obesity treatment and produced substantial early prescription volume. Observers say more time is needed to assess long-term effectiveness and patient retention, and Novo is expected to report first-quarter sales in May that will include the pill.